Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2026-01-08 00:00:00 ET · period of report 2026-01-07 · accession 0001683607-26-000008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-01-08	2026-01-07	REGN	Bassler Bonnie L	Dir	S - Sale+OE	$800.00	-1,500	1,703	-47%	-$1.20M
D	2026-01-08	2026-01-07	REGN	Bassler Bonnie L	Dir	M - OptEx	$374.12	+1,500	3,203	+88%	+$561.2K
D	2026-01-08	2026-01-07	REGN	Bassler Bonnie L	Dir	M - OptEx	$0.00	-1,500	2,861	-34%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-01-07	S	D	1,500	$800.00	1,703	D	—	—	(F2) Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price.
2	Common	Common Stock	2026-01-07	M	A	1,500	$374.12	3,203	D	—	—
3	Derivative	Non-Qualified Stock Option (right to buy)	2026-01-07	M	D	1,500	$0.00	2,861	D	$374.12 · — to 2030-01-02	1,500 Common Stock	(F3) On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.